GlassScriptPhysician profile
Daniel Robert Pfeifer
NPI 1245700723
$5,917.52
in general payments reported to CMS, 2019-2025
27 companies · $856 in 2025
The $856 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $1,391 · 2023: $1,719 · 2024: $1,621 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,195.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.97 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $696.10 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Scilex Pharmaceuticals INC. | $603.76 | 2021-2025 | Ztlido |
| Neurocrine Biosciences, INC. | $538.99 | 2021-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $451.19 | 2021-2024 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $402.29 | 2024-2025 | |
| Ucb, INC. | $338.62 | 2022-2025 | Briviact, Nayzilam |
| Otsuka America Pharmaceutical, INC. | $291.36 | 2022-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $246.34 | 2022 | |
| Eisai INC. | $165.06 | 2021-2025 | |
| Impel Pharmaceuticals INC. | $156.86 | 2022-2023 | Trudhesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.73 | 2022-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $115.47 | 2021 | |
| Amneal Pharmaceuticals LLC | $90.77 | 2023-2024 | Rytary, Crexont |
| Biogen, INC. | $86.70 | 2021-2025 | Leqembi, Vumerity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $79.42 | 2022-2023 | Gralise |
| Sunovion Pharmaceuticals INC. | $59.99 | 2022 | |
| Horizon Therapeutics Plc | $59.35 | 2021-2022 | |
| Neurelis, INC. | $28.13 | 2023 | Valtoco |
| Axsome Therapeutics, INC. | $25.67 | 2025 | Symbravo |
| Genentech USA, INC. | $25.46 | 2024 | Ocrevus, Enspryng |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2024 | Trintellix |
| Argenx US, INC. | $24.00 | 2023 | Vyvgart |
| Livanova USA, INC. | $21.43 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Harmony Biosciences LLC | $19.65 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.99 | 2023 | Keveyis |
| Astrazeneca Pharmaceuticals LP | $15.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pfeifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.